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Abstract
A sophisticated network of BCL-2 family proteins regulates the mitochondria-associated (intrinsic) apoptosis pathway.
Antiapoptotic members such as BCL-XL or MCL-1 safeguard the outer mitochondrial membrane and prevent
accidental cell death in a functionally redundant and/or compensatory manner. However, BCL-XL/MCL-1-mediated
“dual apoptosis protection” also impairs response of cancer cells to chemotherapy. Here, we show that hyperosmotic
stress in the tumor environment abrogates dual BCL-XL/MCL-1 protection. Hypertonicity triggers upregulation of
NOXA and loss of MCL-1 and thereby enforces exclusive BCL-XL addiction. Concomitant targeting of BCL-XL is
sufficient to unlock the intrinsic apoptosis pathway in colorectal cancer cells. Functionally, “osmotic reprogramming” of
the tumor environment grants contextual synthetic lethality to BCL-XL inhibitors in dually BCL-XL/MCL-1-protected
cells. Generation of contextual synthetic lethality through modulation of the tumor environment could perspectively
boost efficacy of anticancer drugs.
Introduction
Elimination of cancer cells mainly relies on activation of
the mitochondria-associated (intrinsic) apoptosis path-
way. This cell death modality is tightly controlled by a
complex network of BCL-2 family proteins. The effector
molecules BAX and/or BAK trigger mitochondrial outer
membrane permeabilization (MOMP), release of cyto-
chrome c, caspase activation and ultimately condemn a
cell to death. BAX and BAK are kept in check by BCL-2,
BCL-XL and/or MCL-1 (collectively also referred to as
BCL-2-like proteins)1. Targeting BCL-2-like proteins
emerged as a therapeutic strategy and spurred develop-
ment of “BH3 mimetics”2. This novel class of anticancer
compounds mimics the function of BH3-only proteins
(the natural antagonists of BCL-2-like proteins) and
unlocks the intrinsic apoptosis pathway. The selective
BCL-2 inhibitor ABT-199 (venetoclax) proved successful
in clinical trials and is meanwhile approved for the
treatment of certain leukemia3. However, functional
redundancy and compensatory roles among the anti-
apoptotic BCL-2-like proteins can establish “code-
pendencies” (e.g. BCL-XL/MCL-1) that hamper efficient
cancer cell elimination when a single BCL-2-like protein
is targeted. Preclinical studies demonstrated that inhibi-
tion of two or more BCL-2-like proteins was required to
overcome this limitation4–7. Our previous work showed
that cancer cells facing a hypertonic environment exhib-
ited a lower threshold for MOMP induction8–10. We
hypothesized that this could reflect hypertonicity-induced
alterations in the BCL-2 family network. How hyper-
osmotic stress affects cancer cells has not been compre-
hensively investigated, but reports document enhanced
cisplatin sensitivity, secretion of angiogenesis-promoting
cytokines and upregulation of resistance- or metastasis-
associated proteins11–14.
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Here, we show that hypertonicity can alter code-
pendencies of cancer cells on BCL-2-like proteins.
Hyperosmotic stress shrinks dual BCL-XL/MCL-1 pro-
tection to exclusive BCL-XL addiction by upregulation of
NOXA and concomitant loss of MCL-1. This renders
selective BCL-XL inhibition sufficient for activation of the
intrinsic apoptosis pathway. Functionally, “osmotic
reprogramming” of the tumor environment grants con-
textual synthetic lethality to BCL-XL inhibitors in dually
BCL-XL/MCL-1-protected cancer cells. Perspectively, our
findings could boost the efficacy of anticancer drugs.
Results
BCL-XL/MCL-1 coinhibition triggers BAX/BAK-dependent
apoptosis in colorectal cancer cells
Challenging HCT116 cells with ABT-737 (targeting
BCL-2, BCL-XL and BCL-W), WEHI-539 (targeting BCL-
XL) and ABT-199 (targeting BCL-2) only marginally kil-
led cancer cells (Fig. 1a)15–18. However, combination with
the MCL-1-selective inhibitor S6384518,19 drastically
enhanced ABT-737 and WEHI-539 (but not ABT-199)
cytotoxicity (Fig. 1a, e, f) and even synergized in cell death
induction (Supplementary Table 1). This suggested a
BCL-XL/MCL-1 codependency and implicated that both
(a) were involved in maintaining integrity of the outer
mitochondrial membrane and (b) exhibited functional
redundancy with compensatory roles. Expectedly, com-
binatorial treatment with S63845 and other BCL-XL-
selective inhibitors (A1155463 or A1331852) also syner-
gistically induced cell death (Fig. 1b, Supplementary Table
1)20,21. Coinhibition of BCL-XL/MCL-1 resulted in
annexin-V/7-AAD positivity (Fig. 1c) and critically
depended on the pore-forming proteins BAX and BAK for
cytotoxic effects (Fig. 1d–f). In sum, our results indicated
that BCL-XL and MCL-1 safeguarded mitochondrial
integrity in a functionally redundant manner, which
necessitated dual BCL-XL/MCL-1 inhibition for efficient
activation of the intrinsic apoptosis pathway.
Hyperosmotic stress renders selective BCL-XL inhibition
sufficient for cell death induction
In previous work, we showed that hyperosmotic stress
facilitates MOMP induction8–10. Hyperosmotic stress (or
hypertonicity) occurs when osmotically active solutes
(such as NaCl) cannot passively diffuse across the plasma
membrane and thus establish an osmotic pressure gra-
dient between the extra- and intracellular space. Notably,
hypertonicity and BCL-XL-selective BH3 mimetics
synergized in cell death induction and abrogated the
necessity of concomitant MCL-1 inhibition (Fig. 2a–c,
Supplementary Table 2). In contrast, inhibition of MCL-1
was not cytotoxic (Fig. 2d). Targeting BCL-XL under
hyperosmotic stress was associated with annexin-V/7-
AAD positivity (Fig. 2e) and increased activity of the
effector caspases 3 and 7 (Fig. 2f) while loss of BAX/BAK
rescued cells from cytotoxic effects (Fig. 2g). Collectively,
our data suggested that hyperosmotic stress counteracted
the antiapoptotic function of MCL-1 and thereby ren-
dered BCL-XL inhibition sufficient for apoptosis induc-
tion. Functionally, combination of BCL-XL inhibitors and
hyperosmotic stress resulted in contextual synthetic
lethality.
Hypertonicity-imposed contextual synthetic lethality is
selective for BCL-XL-targeting drugs
We assessed whether other drugs also displayed
enhanced cytotoxicity under hypertonic conditions and
screened a library comprising 110 well-characterized
apoptosis-inducing compounds. Hypertonicity only
boosted cancer cell killing of BCL-XL targeting drugs
such as A1155463, A1331852, ABT-737 and navitoclax
(ABT-263), but not other compounds (Supplementary
Fig. 1 and Supplementary Tables 3, 4). Hyperosmotic
stress apparently granted contextual synthetic lethality
specifically to BCL-XL targeting drugs.
NOXA upregulation is critical for hypertonicity-enforced
BCL-XL addiction
We next investigated whether the hypertonicity-
induced shift from BCL-XL/MCL-1 codependency to
exclusive MCL-1 addiction (Fig. 2a–c) was due to changes
in the network of BCL-2 family proteins. We first focused
on transcriptional changes under hyperosmotic stress.
Exposing HCT116 cells to 60mM NaCl for 1−4 h caused
upregulation of BIM, NOXA and (to a lesser extent)
PUMA (Fig. 3a). These early hypertonicity-induced
changes did not affect interaction of BCL-XL with BAX
and proapoptotic BH3-only proteins (Fig. 3b), but slightly
reduced binding of BIM to MCL-1 (Fig. 3c). After 24 h,
BIM and PUMA upregulation was even more prominent
along with enhanced transcription of BID, MCL-1, BCL-
XL, BAX and BAK (Fig. 3a). BAX is essential for MOMP
in HCT116 cells and its activation is controlled by inter-
action with MCL-1 and BCL-XL5,22,23. Coimmunopreci-
pitation experiments, however, failed to demonstrate
hypertonicity-induced changes of BCL-XL/MCL-1 inter-
action with BAX (Fig. 3d). We next investigated the
functional relevance of hypertonicity-induced BCL-2
family protein upregulation for exclusive BCL-XL addic-
tion. Genetic loss of the directly BAX-activating proteins
BID or BIM failed to rescue NaCl/WEHI-539-treated
cells24,25 whereas loss of BAX (but not BAK) expectedly
did (Fig. 3e). PUMA-deficiency somewhat attenuated
NaCl/WEHI-539 cytotoxicity. Surprisingly, deficiency in
the MCL-1 interacting BH3-only Protein NOXA granted
almost full-blown protection to NaCl/WEHI-539 treat-
ment (Fig. 4a and Supplementary Fig. 2a)26. Notably,
NOXA-deficient cells still relied on BCL-XL/MCL-1 to
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safeguard mitochondrial integrity as they were readily
killed upon dual BCL-XL/MCL-1 inhibition (Fig. 4b). In
line with the transient transcriptional upregulation of
NOXA (Figs. 3a and 4f), protein levels peaked approxi-
mately 4 h after addition of NaCl and subsequently
declined (Fig. 4c, e). This could reflect proteasomal
degradation as NOXA is efficiently eliminated via the
proteasome and proteasome inhibition consequently
caused NOXA accumulation (Fig. 4d)27. Hyperosmotic
stress did not prolong the half-life of the relatively
Fig. 1 BCL-XL/MCL-1 coinhibition triggers apoptosis in colorectal cancer cells. a, b Cells were challenged with the indicated concentrations of
a ABT-737, WEHI-539 and ABT-199 or b A1155463 and A1331852 for 18 h in the presence and absence of the MCL-1 inhibitor S63845. c HCT116 cells
were challenged with WEHI-539 and S63845 for 6 h and subsequently analyzed by flow cytometry for 7-AAD- and annexin-V positivity. d–f BAX/BAK-
deficient HCT116 cells, DLD1 cells, SW48 cells and BAX/BAK-deficient variants thereof were challenged with the indicated concentrations of WEHI-
539, A1155463 and A1331852 for 18 h in the presence and absence of the MCL-1 inhibitor S63845. For (a, b, d–f), data points and mean ± SEM from
three independent experiments are shown; for (c), data shown are representative of two experiments performed.
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Fig. 2 Hyperosmotic stress renders exclusive BCL-XL inhibition sufficient for cell death induction. a–d Cells were challenged with the
indicated concentrations of WEHI-539, A1155463, A1331852 and S63845 for 18 h in the presence and absence of the indicated concentrations of
NaCl. e HCT116 cells were challenged with WEHI-539 (0.6 µM) and NaCl (60 mM) for 4 h and subsequently analyzed by flow cytometry for 7-AAD- and
annexin-V positivity. f HCT116 cells were treated with the BCL-XL inhibitors WEHI-539, A1155463 and A1331852 in the presence and absence of NaCl
(60 mM). Caspase-3/-7 activity was assessed using the fluorogenic substrate (DEVD)2-R110. g BAX/BAK-deficient variants of HCT116, DLD1 and SW48
cells were challenged with the indicated concentrations of A1155463 and A1331852 (both BCL-XL selective) for 18 h in the presence and absence of
the indicated concentrations of NaCl. For (a–d, f and g), data points and mean ± SEM from three independent experiments are shown; for (e), data
shown are representative of two experiments performed. RFU relative fluorescence units.
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short-lived NOXA (Fig. 4g), again indicating that the
observed transient NOXA accumulation is most probably
attributable to increased transcription. Transcriptional
upregulation of NOXA has previously been linked to ER
stress (with subsequent activation of the transcriptional
regulators ATF4 and ATF6) and/or p5328,29. However,
exposure to 60mM NaCl for 4 h showed no signs of ATF4
and ATF6 activation (Fig. 5a). Hypertonicity-mediated
NOXA-induction also occurred in a p53-independent
manner. Addition of NaCl increased p53 mRNA and
protein levels (Fig. 5b, c), but p53-deficiency still allowed
NOXA upregulation upon NaCl treatment (Fig. 5d).
Together, our data demonstrated that transient tran-
scriptional upregulation of NOXA by a not-yet identified
Fig. 3 Hypertonicity increases transcription of BCL-2 family proteins without affecting interaction of BCL-XL/MCL-1 with BAX. a HCT116
cells were challenged with NaCl (60 mM) for the indicated periods. mRNA levels of genes encoding the indicated proteins were analyzed by qPCR.
Shown are data points and mean from two independent experiments. b, c HCT116 cells were challenged with NaCl (60 mM), WEHI-539 (1.25 µM) and
S63845 (2.5 µM) for 5 h. After washing and cell lysis, immunoprecipitation was performed with antibodies specific for b BCL-XL and c MCL-1.
Immunoprecipitates were analyzed together with the corresponding lysates by western blotting using antibodies specific for the indicated proteins.
The BCL-XL inhibitor WEHI-539 and the MCL-1 inhibitor S63845 served as positive/negative controls. d HCT116 cells were challenged with NaCl
(60 mM) for 24 h or left untreated. Immunoprecipitation was performed as described in (b). For (b–d), data shown are representative of at least two
experiments performed. e HCT116 cells and BID-, BIM-, PUMA-, BAX-, and BAK-deficient variants thereof were challenged with the indicated
concentrations of WEHI-539 for 18 h in the presence and absence of NaCl (60 mM). Data points and mean ± SEM from three independent
experiments are shown.
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mechanism was essential for contextual synthetic lethality
of hypertonicity and BCL-XL inhibition.
Accumulation of NOXA is accompanied by decline of MCL-
1 levels
Thus far, we demonstrated that hypertonicity (a)
facilitated MOMP induction, (b) shrank dual BCL-XL/
MCL-1 protection to exclusive BCL-XL addiction and (c)
triggered upregulation of NOXA, a MCL-1 interacting
BH3-only protein. We next assessed the interrelations of
these observations. NOXA is capable to facilitate or
induce MOMP through direct interaction with and acti-
vation of BAX or targeting MCL-1 for proteasomal
degradation30–32. Coimmunoprecipitation experiments
Fig. 4 Contextual synthetic lethality of BCL-XL inhibitors under hyperosmotic conditions is NOXA dependent. a Left panel: HCT116 cells and
NOXA-deficient variants thereof were challenged with the indicated concentrations of WEHI-539 for 18 h in the presence and absence of NaCl (60mM).
Right panel: Western blot analysis of NOXA levels in HCT116, HCT116 shNOXA and HCT116 shControl cells in the presence and absence of NaCl (60mM).
b Cells were challenged with the indicated concentrations of WEHI-539 in the presence and absence of the indicated concentrations of the MCL-1
inhibitor S63845 for 18 h. c, e Cells were challenged with NaCl (HCT116: 60mM, DLD1: 90mM) for the indicated periods. After washing and cell lysis,
western blot analyses were performed with antibodies specific for the indicated proteins. Detection of tubulin served as a loading control. d HCT116
cells were challenged with NaCl (60 mM) in the presence and absence of the proteasome inhibitor bortezomib (10 nM). Changes in cellular NOXA levels
were analyzed by western blotting. f DLD1 cells were challenged with NaCl (90 mM) for the indicated periods. PMAIP1 mRNA levels (encoding NOXA)
were analyzed by qPCR. g HCT116 cells were treated with NaCl (75mM) for the indicated periods of time in the presence and absence of cycloheximide
(CHX, 5 µg/mL), an inhibitor of protein translation. Western blot analysis was performed as in (c). For (a, b and f), data points and mean ± SEM from three
independent experiments are shown. For (c–e and g), data shown are representative of at least two independent experiments performed.
Knoll et al. Cell Death and Disease          (2020) 11:257 Page 6 of 11
Official journal of the Cell Death Differentiation Association
did not point to a direct NOXA/BAX interaction during
hyperosmotic stress (Fig. 6a). However, hypertonicity-
induced NOXA upregulation was followed by a decline in
MCL-1 levels that recovered when NOXA expression at
later time points returned to baseline (Fig. 4c). NOXA can
interact with and target MCL-1 for proteasomal degra-
dation33–36. Indeed, we observed that NOXA-deficiency
significantly impaired decrease of MCL-1 levels under
hyperosmotic stress (Fig. 6b). However, MCL-1 levels
started to decline as early as 2 h after exposure to NaCl
(Fig. 6b and Supplementary Fig. 2b), whereas NOXA
upregulation was only detectable after 4 h (Fig. 6b).
Additionally, coimmunoprecipitation experiments showed
reduced (rather than the expected enhanced) binding of
NOXA to MCL-1 under hypertonic conditions (Fig. 3c).
These observations suggested that mechanisms other than
NOXA upregulation (e.g., translational repression37)
might account for or contribute to loss of MCL-1 during
hyperosmotic stress. As hypertonicity-induced NOXA
upregulation peaked approximately 4 h after addition of
NaCl and subsequently declined (Fig. 4c), NOXA-
mediated contextual synthetic lethality of hyperosmotic
stress and BCL-XL inhibitors should depend on the timing
of hypertonicity-induction and BCL-XL inhibition. Indeed,
NOXA-proficient cells displayed enhanced WEHI-539
cytotoxicity upon simultaneous NaCl/WEHI-539
treatment. However, preincubation with NaCl for 18 h
allowed re-adjustment of NOXA levels to baseline (Fig. 4c, e)
and BCL-XL inhibition was consequently not cytotoxic
(Fig. 6c). NOXA-deficiency expectedly protected HCT116
cells from WEHI-539-mediated cytotoxicity in presence of
NaCl. Our data thus suggested that hyperosmotic stress
temporarily and inversely affected cellular levels of MCL-1
and NOXA. Functionally, this resulted in transient
exclusive BCL-XL dependency.
Discussion
Our study demonstrates that hypertonicity-induced,
transient upregulation of NOXA counteracts the anti-
apoptotic function of MCL-1 and temporarily renders
dually BCL-XL/MCL-1-protected cells exclusively BCL-XL-
dependent. During this period, concomitant targeting of
BCL-XL is sufficient to initiate MOMP (Fig. 6d). Func-
tionally, we demonstrate contextual synthetic lethality of
BCL-XL inhibitors in an exogenously modified, hypertonic
tumor environment (“osmotic reprogramming”) and pro-
vide insight into the underlying molecular mechanism that
critically involves NOXA. This BH3-only protein deter-
mines sensitivity to BCL-XL targeting BH3 mimetics in
various cancer entities32,38–41. In previous work, we showed
that hyperosmotic stress is capable to facilitate activation of
the intrinsic apoptosis pathway8–10,42. However, in these
Fig. 5 Hypertonicity-induced NOXA upregulation is not related to ER stress and independent of p53. a Cells were challenged with NaCl
(60 mM) and tunicamycin (2 µg/mL), an inducer of endoplasmic reticulum stress. After washing and cell lysis, western blot analyses were performed
with antibodies specific for the indicated proteins. Detection of tubulin served as a loading control. b HCT116 cells were challenged with NaCl in the
indicated concentrations for 5.5 h. TP53 mRNA levels were analyzed by qPCR. c HCT116 cells were challenged with the indicated concentrations of
NaCl for 18 h and subsequently analyzed by western blotting as in (a). Hypertonicity-induced phosphorylation of Ser15 indicates functional activation
of p53. d Left panel: HCT116 cells and p53-deficient variants thereof were challenged with NaCl (60 mM) for the indicated periods. mRNA levels of the
NOXA-encoding gene PMAIP1 were analyzed by qPCR. Right panel: Western blot analysis of p53 levels in UV-treated HCT116 and HCT116 p53 KO
cells. For (a and c), data shown are representative of at least two independent experiments performed. For (b and d), data points and mean ± SEM
from three independent experiments are shown.
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studies we repeatedly failed to detect hypertonicity-induced
disturbances in the BCL-2 protein family network. Retro-
spectively, this was for the simple reason that we left early,
transient changes out of consideration. Instead, we looked
for alterations after 18 or 24 h of NaCl treatment, when
cytotoxic effects of BCL-XL inhibitor became apparent. Our
reasoning that hypertonicity-induced changes in cellular
levels of BCL-2 family proteins should be observable at the
time of measurable cytotoxicity proved false. The current
study highlights that hypertonicity-induced upregulation of
NOXA and decline in MCL-1 levels are both transient
events. Consequently, exclusive BCL-XL addiction and
contextual synthetic lethality of BCL-XL inhibitors is
restricted to a certain window (Fig. 6d). A transient decrease
Fig. 6 NOXA upregulation and concomitant MCL-1 loss shifts BCL-XL/MCL-1 codependency to exclusive BCL-XL addiction. a HCT116 cells
were challenged with NaCl (60 mM) for 5 h. After washing and cell lysis, immunoprecipitation was performed with antibodies specific for BAX (left
panel) and NOXA (right panel). Immunoprecipitates were analyzed together with the corresponding lysates by western blotting using antibodies
specific for the indicated proteins. b HCT116 shNOXA and corresponding controls were challenged with NaCl (60 mM) for the indicated periods.
MCL-1 and NOXA levels were analyzed by western blotting with antibodies specific for the indicated proteins. c Cells were challenged with the
indicated concentrations of WEHI-539, either simultaneously with NaCl (60 mM) or after 18 h NaCl preincubation. Viability was assessed by MTT
staining. d Proposed model of hypertonicity-granted contextual synthetic lethality of BCL-XL inhibition. Left panel: under isotonic conditions, BCL-XL
and MCL-1 both safeguard mitochondrial integrity in a functionally redundant and compensatory manner. Due to this dual protection, the cell’s
readiness to undergo apoptosis (“death priming”) is low. Middle panel: Hyperosmotic stress triggers transient upregulation of NOXA and temporary
decline in MCL-1 levels. Functionally, this generates exclusive BCL-XL-addiction for a limited period. Right panel: Targeting BCL-XL during the time of
exclusive BCL-XL dependency irrevocably triggers mitochondrial outer membrane permeabilization (MOMP) and is contextually synthetically lethal.
n.d. not detected.
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in cellular MCL-1 levels under hypertonic conditions was
already observed earlier37. We also noticed that (in contrast
to NOXA) hypertonicity-induced upregulation of BIM-
encoding mRNA (Fig. 3a) did not translate into increased
protein levels (Fig. 3b,c). This could reflect translational
repression and/or changes mRNA stability37,43. Interest-
ingly, BCL-XL inhibitors induced apoptosis under hyper-
osmotic conditions in the absence of BIM (Fig. 3e). A
previous study, however, convincingly demonstrated that
NOXA-triggered release of BIM from MCL-1 was essential
for BAX/BAK activation44. Our results resemble findings
from another study that showed dispensability of BIM (and
other BH3-only proteins) for apoptosis induction when
MCL-1 and BCL-XL are inhibited5. Whether attenuated
cytotoxicity of NaCl/WEHI-539 in PUMA-deficient cells
indicates involvement of PUMA in hypertonicity-enforced
BCL-XL addiction requires further studies (Fig. 3e).
Biophysical factors in the environment of tumors (such
as low oxygen levels or elevated pressure) enforce adap-
tion of cancer cells to ensure survival. The resulting cel-
lular processes have thus far mainly been recognized as
drivers of non-cell-autonomous resistance to treatment45.
Vice versa, interfering with these environment-imposed
adaptive cellular responses is often lethal for cancer cells
and is known as contextual synthetic lethality46. Indeed,
environment-based contextual synthetic lethality has been
recognized as potential therapeutic target46–48. Our cur-
rent study advances the concept of contextual synthetic
lethality inasmuch as we exogenously modified biophysi-
cal properties in the tumor environment (“osmotic
reprogramming”) in a way that allowed hijacking a cancer
cell’s adaptive response. Therapeutic exploitation of our
findings has of course limitations. For practical reasons,
artificial generation of hyperosmotic stress around tumors
is conceivable in solid cancers that are easily reachable,
but hardly for e.g. leukemia. Notably, our data indicate
that exposure of cancer cells to osmotically active solutes
for just a couple of hours is sufficient to promote NOXA
upregulation (Figs. 3a and 4c). Even transient hypertoni-
city could therefore be sufficient to render concomitant
BCL-XL inhibition deleterious for cancer cells. Moreover,
contextual synthetic lethality of hyperosmotic stress and
selective inhibition of BCL-2-like proteins might only be
achievable in cells that are (a) capable to upregulate
NOXA and (b) exhibit a codependency that can be tar-
geted by NOXA (e.g. MCL-1 or BFL-1). While we found
clear evidence for hypertonicity-induced, transient tran-
scriptional upregulation of NOXA (Fig. 3a), the under-
lying signaling cascades and transcription factor(s)
involved remain to be determined. Our approach addi-
tionally requires codependency on BCL-2-like proteins
that are druggable. There are to date no selective inhibi-
tors for BCL-W, which can render cancer cells non-
responsive to BCL-XL and MCL-1 inhibition4. However,
tools to individually decipher the dependencies of cancer
cells on BCL-2-like proteins are available and allow (at
least to some extent) to predict treatment response
beforehand2,49. Nevertheless, our study provides evidence
that reprogramming biophysical factors in the tumor
environment can alter dependency of cancer cells on
BCL-2-like proteins and thereby grant contextual syn-
thetic lethality to BH3 mimetics.
Material and methods
Cell lines, antibodies and reagents
HCT116 cells were obtained from the German Collec-
tion of Microorganisms and Cell Culture (DSMZ,
Braunschweig, Germany). HCT116 BAX/BAK DKO and
HCT116 BAK KO cells were kindly provided by Richard
Youle (National Institutes of Health, Bethesda, USA)22.
HCT116 BAX KO cells were obtained from Bert Vogel-
stein (Johns Hopkins University, Baltimore, MA, USA)50,
BID-deficient HCT116 cells were a kind gift from Xu Luo
(University of Nebraska Medical Center, Nebraska,
USA)51, HCT116 BIM KO cells were provided by Hamsa
Puthalakath (La Trobe University, Bundoora, Australia)52,
HCT116 shNOXA and HCT116 shCtr cells have been
described previously53. HCT116 PUMA KO cells were
purchased from Horizon Discovery (Cambridge, UK)54.
SW48 and DLD1 cells and BAX/BAK-deficient variants
thereof were purchased from Sigma (Steinheim, Ger-
many). All cell lines were maintained in RPMI 1640
medium (PAN Biotech, Aidenbach, Germany) with 10%
(v/v) fetal calf serum (Sigma). Antibodies: ATF4 (#11815),
ATF6 (#65880), BID (#2002), BIM (#2933), BAX (#5023),
BAK (#12105), PUMA (#12450), BCL-XL (#2764), p53
(#4866); phospho-p53 (#9284) Cell Signaling (Beverly,
MA, USA); MCL-1 (ab32087): abcam (Cambridge, UK);
tubulin (#MS-581): Dunnlab (Asbach, Germany); NOXA
(114C307, #sc-56169): Santa Cruz (Santa Cruz, CA, USA).
Chemicals: MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyl tetrazolium bromide), cycloheximide: Biomol (Ham-
burg, Germany); A1155463, A1331852, ABT-199, ABT-
737, S63845, WEHI-539 and apoptosis compound library
(HY-L003): Hycultec (Beutelsbach, Germany).
MTT-based cell viability assay
Cells were seeded in 96-well plates (2 × 104 cells/well)
and challenged with the indicated concentrations of the
indicated substances in duplicates (technical replicates).
Unless indicated otherwise, cell viability was determined
18 h after stimulation using MTT staining (2 h at 37 °C).
Staining intensity was measured at 595 nm and the mean
was calculated from the technical replicates of each
experiment. The mean value for untreated controls was
set to 100%. For any other condition, the MTT staining
intensity is given relative to the corresponding untreated
group (% of control). Data points shown are mean values
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(calculated from two technical replicates) of independent
experiments (n ≥ 2).
Western blot analysis
Cells were harvested by centrifugation and lysed in 4×
Laemmli sample buffer (8% [w/v] SDS, 0.1M dithio-
threitol, 40% [v/v] glycerol, 0.2M Tris, pH 8.0) supple-
mented with phosphatase inhibitor cocktails-I and -II
(Sigma). Samples were sonicated and boiled for 5 min at
96 °C before proteins were separated by SDS-PAGE and
transferred to polyvinylidene difluoride membranes. To
block nonspecific binding sites, membranes were incu-
bated in Tris-buffered saline containing 0.1% (v/v) Tween
20 and 5% (w/v) dry milk before primary antibodies of the
specificity of interest were added. Antigen−antibody
complexes were visualized using horseradish peroxidase-
conjugated secondary antibodies (Dako, Hamburg, Ger-
many) and ECL technology (Pierce, Rockford, IL, USA).
Coimmunoprecipitation
HCT116 cells (8 × 106 cells per condition) were chal-
lenged with the indicated substances for the indicated
periods. After washing with ice-cold PBS, cell were lysed
in MCBL-buffer (NP40 0.5% [v/v], 150mM NaCl, 50 mM
Tris, pH 7.4) supplemented with completeTM protease
inhibitor cocktail (Roche, Mannheim, Germany) for
40min on ice. Lysates were cleared by centrifugation
(20,000 × g, 20 min, 4 °C) and incubated overnight with a
1:200 dilution of BCL-XL-, MCL-1-, BAX- and NOXA-
specific antibodies at 4 °C. The next day,
antigen–antibody complexes were precipitated using
protein G agarose (Roche). After washing in lysis buffer,
agarose-bound proteins were eluted by incubation at
95 °C in Laemmli sample buffer (10 min) and analyzed
together with the corresponding lysates by western
blotting.
Quantitative PCR
Total RNAs were isolated with the RNeasy mini kit
(Qiagen, Valencia, CA, USA), according to the manu-
facturer’s instructions. Two micrograms of total RNA was
transcribed into complementary DNA using the high-
capacity cDNA reverse transcription kit (Applied Biosys-
tems, Carlsbad, CA, USA). Quantification of mRNA levels
of the following genes was done using TaqMan gene
expression assays (Applied Biosystems) and an ABI Prism
7900 sequence detector (Applied Biosystems): PMAIP1
(#Hs00560402_m1), BCL2L1 (#Hs00236329_m1), BAK1
(#Hs00832846_g1), BBC3 (#Hs00248075_m1), MCL1
(#Hs01050896_m1), BCL2L11 (#Hs01076940_m1), BID
(#Hs00609632_m1), BAX (#Hs00180269_m1), TP53
(#Hs01034249_m1). qRT-PCR reactions were performed
in triplicates for each sample and were normalized to the
expression of the housekeeping gene HPRT1
(Hs02800695_m1). mRNA levels were calculated using
the SDS 2.1 software (Applied Biosystems).
Flow cytometry
Cell death was assessed by annexin-V and 7-
aminoactinomycin D (7-AAD) staining. In brief,
HCT116 cells were challenged with WEHI-539 and
S63845 for 24 h or left untreated. Afterwards, cells were
stained with 7-AAD and annexin-V (4 °C for 15min in the
dark) and analyzed immediately using a FACSCanto flow
cytometer (BD Biosciences, Heidelberg, Germany) fol-
lowing standard procedures55.
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